In 10–25% of breast cancer cases, a key prognostic marker and effective therapeutic target for breast cancer is the human epidermal growth factor receptor 2 (HER2) (Slamon et al., 1987; Owens et al., 2004). Here, ERBB2 is linked to breast carcinoma.